Psych CASC / OSCE · Psychopharmacology — antipsychotics
Explaining antipsychotic choice and metabolic monitoring (CASC)
CASC-style communication station: shared decision on antipsychotic choice, metabolic risk, monitoring plan, and myths about addiction/strength.
On this page & tools
Target exams
Station instructions (candidate)
You have 7 minutes. Explain recommended antipsychotic treatment for first-episode psychosis to a concerned parent, including benefits, metabolic monitoring, and what happens if the first medicine does not help. Avoid jargon without explanation. Do not guarantee cure. Anchor explanations in effectiveness evidence and early intervention models rather than brand slogans.[1][3]
Marking domains
Mark empathy and agenda setting; accurate plain-language mechanism (dopamine signalling, not a "personality drug"); shared decision reflecting metabolic priorities informed by comparative evidence; a concrete monitoring plan; safety-net and early intervention team role; no over-promise and no stigma. These domains mirror real CASC priorities and the evidence that multi-element early care beats tablet choice alone.[3]
Model communication map
- Open: thank them; check understanding of psychosis; name shared goals (safety, thinking clearer, return to study/work).[3]
- Medicine role: reduces intensity of distressing beliefs/voices for many people; works with psychological and family support, not instead of them.[3]
- Choice: explain why a lower-metabolic option may fit their priorities better than the "strongest marketing" agent; evidence shows different trade-offs, not one universal winner.[1][2]
- Monitoring: weight, bloods, how often; lifestyle support — physical health is part of antipsychotic care.[2]
- If first fails: switch once; if two proper trials fail, specialist medicines such as clozapine exist — do not frighten, do not withhold hope.[2]
- Addiction myth: not recreationally addictive like opioids; stopping needs medical planning because illness can return.[1]
- Close: questions, written info, crisis contacts.[3]
Common fails
- Dismissing metabolic fears despite clear comparative tolerability differences.[1][2]
- Saying "atypicals have no side-effects" — false and examinable.[1]
- Skipping monitoring plans that every guideline-oriented viva expects.[2]
- Threatening forced medication as first communication move without legal/clinical context.[3]
References
- [1]Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med, 2005.PMID 16172203
- [2]Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis Lancet, 2013.PMID 23810019
- [3]Kane JM, Robinson DG, Schooler NR, et al. Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program Am J Psychiatry, 2016.PMID 26481174